Research Topics
| H H BaileySummaryAffiliation: University of Wisconsin Country: USA Publications
| Collaborators
|
Detail Information
Publications
A phase II trial of daily perillyl alcohol in patients with advanced ovarian cancer: Eastern Cooperative Oncology Group Study E2E96Howard H Bailey
University of Wisconsin Madison, Madison, Wisconsin 53792, USA
Gynecol Oncol 85:464-8. 2002..Perillyl alcohol was administered orally, four times daily, at a dose of 1200 mg/m(2). This was repeated until disease progression or unacceptable toxicity was experienced...- A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 daysHoward H Bailey
University of Wisconsin Comprehensive Cancer Center, K6 568 CSC, 600 Highland Avenue, Madison, WI 53792 5669, USA
Cancer Chemother Pharmacol 54:368-76. 2004..A phase I study of POH for 14 days out of every 28 days in subjects with advanced malignancies was performed to evaluate dose escalation, toxicity, pharmacokinetics, and effects on TGFbeta and Ras... - Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalanH H Bailey
Department of Medicine, University of Wisconsin Comprehensive Cancer Center, Madison 53792, USA
J Natl Cancer Inst 89:1789-96. 1997.... - L-S,R-buthionine sulfoximine: historical development and clinical issuesH H Bailey
University of Wisconsin Comprehensive Cancer Center, Department of Medicine, Madison 53792, USA
Chem Biol Interact 111:239-54. 1998..Evidence of clinical activity has been observed in patients with alkylating or platinating agent-refractory tumors. Phase II evaluation of CI BSO with L-PAM is in progress... - Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancerHoward H Bailey
University of Wisconsin Paul P Carbone Comprehensive Cancer Center, 600 Highland Avenue K4 6 CSC, Madison, WI 53792, USA
Cancer Chemother Pharmacol 62:149-57. 2008..We conducted a phase II multi-institutional study of oral POH administered four times daily in women with advanced treatment-refractory breast cancer... 
Green tea polyphenols for prostate cancer chemoprevention: a translational perspectiveJ J Johnson
University of Wisconsin School of Pharmacy, Division of Pharmacy Practice, 1031 Rennebohm Hall, Madison, WI, USA
Phytomedicine 17:3-13. 2010..The data that has been collected so far suggests that green tea may be a promising agent for PCa chemoprevention and further clinical trials of participants at risk of PCa or early stage PCa are warranted...- Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trialDavid M Kushner
Division of Gynecologic Oncology, University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, and Regional Cancer Center at Oconomowoc Waukesha Memorial Hospitals, WI, USA
Gynecol Oncol 105:358-64. 2007..The optimal specific combination has yet to be determined. The current study evaluates weekly docetaxel and carboplatin in this setting... - Phase II study of daily oral perifosine in patients with advanced soft tissue sarcomaHoward H Bailey
University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin 53792, USA
Cancer 107:2462-7. 2006.... - Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: a Wisconsin Oncology Network StudyBrad S Kahl
Department of Medicine, University of Wisconsin Comprehensive Cancer Center, University of Wisconsin Medical School, Madison, WI 53792, USA
Cancer Invest 23:13-8. 2005..The response rate appears similar to other reports using different doses and schedules. Myelosuppression appears less with this schedule than with other schedules... - Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignanciesSteven Attia
University of Wisconsin Paul P Carbone Comprehensive Cancer Center Madison, Madison, WI 53792, USA
Cancer Chemother Pharmacol 64:45-51. 2009..To define dose limiting toxicities (DLTs) and the maximum tolerated dose (MTD) of capecitabine with fixed-dose rate (FDR) gemcitabine... - A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of {alpha}-difluoromethylornithine in subjects with previous history of skin cancerHoward H Bailey
University of Wisconsin Paul P Carbone Cancer Center, Madison, USA
Cancer Prev Res (Phila) 3:35-47. 2010..069) in new NMSC that was predominantly due to a marked reduction in new BCC. Based on these data, the potential of DFMO, alone or in combination, to prevent skin cancers should be explored further... - Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridolJames P Thomas
University of Wisconsin Comprehensive Cancer Center, University of Wisconsin Medical School, 600 Highland Ave, Madison, WI 53792, USA
Cancer Chemother Pharmacol 50:465-72. 2002..The manageable gastrointestinal toxicity, early signs of clinical activity and lack of hematologic toxicity make further exploration in combination trials warranted... - Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignanciesAnne M Traynor
University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, WI 53792, USA
Invest New Drugs 29:316-22. 2011..To assess the safety, maximum-tolerated dose (MTD), and dose-limiting toxicities (DLT), of motexafin gadolinium (MGd), given in combination with doxorubicin, in patients with advanced solid tumors... - Phase I trial of weekly paclitaxel and BMS-214662 in patients with advanced solid tumorsHoward H Bailey
University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, Wisconsin 53792, USA
Clin Cancer Res 13:3623-9. 2007..To assess the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacodynamics, and antitumor activity of continuous weekly-administered paclitaxel and BMS-214662, a novel farnesyl transferase inhibitor... - Gemcitabine, Paclitaxel, and piritrexim: a phase I studyGlenn Liu
University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, USA
Am J Clin Oncol 26:280-4. 2003..The combination of these new antifolates with paclitaxel and gemcitabine appears safe and should be considered for phase II trials in known responsive tumors such as transitional cell carcinomas... - Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network studyJ E Chang
Paul P Carbone Comprehensive Cancer Center, University of Wisconsin, Madison, WI, USA
Hematol Oncol 27:11-6. 2009..As(2)O(3) and AA in this novel dosing strategy was generally well tolerated but had limited activity in patients with relapsed and refractory lymphoid malignancies... - Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology NetworkB S Kahl
Department of Medicine, University of Wisconsin, Madison, WI, USA
Ann Oncol 17:1418-23. 2006..There is no standard first line treatment for mantle cell lymphoma... - Constitutive and beta-naphthoflavone-induced expression of the human gamma-glutamylcysteine synthetase heavy subunit gene is regulated by a distal antioxidant response element/TRE sequenceR T Mulcahy
Department of Human Oncology, University of Wisconsin Medical School, Madison, Wisconsin 53792, USA
J Biol Chem 272:7445-54. 1997..Collectively the data indicate that the constitutive and beta-NF-induced expression of the human GCS heavy subunit gene is mediated by a distal ARE sequence containing an embedded tetradecanoylphorbol-13-acetate-responsive element... - Non-Hodgkin's lymphoma presenting as a pelvic mass with elevated CA-125Gregory W Allen
Department of Human Oncology, University of Wisconsin Hospital and Clinics, Madison, WI 53792, USA
Gynecol Oncol 94:811-3. 2004..While ovarian cancer is high on the list of differential diagnoses, lymphoma cannot be excluded until a tissue diagnosis is obtained... - Progress of a Comprehensive Familial Cancer Genetic Counseling Program in the Era of BRCA1 and BRCA2Ellen M Hartenbach
University of Wisconsin Comprehensive Cancer Center, Gynecologic Oncology Program, Madison 53792, USA
Genet Test 6:75-8. 2002..In our program, the majority of families counseled were eligible for BRCA1/BRCA2 testing, but only 18% have elected to proceed at this time... - Phase II study of 1alpha-hydroxyvitamin D(2) in the treatment of advanced androgen-independent prostate cancerGlenn Liu
Department of Medicine, Medical Oncology Section, University of Wisconsin Comprehensive Cancer Center, 600 Highland Avenue, Madison, WI 53792, USA
Clin Cancer Res 9:4077-83. 2003..CONCLUSION: The results of this and other trials suggest further clinical investigation in this disease with vitamin D analogues alone or in combination with other agents, such as chemotherapy, should be pursued... - A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group studyDeborah K Armstrong
John Hopkins Kimmel Cancer Center, Bunting Blaustein Cancer Research Building, Baltimore, MD 21231 1000, USA
Gynecol Oncol 103:391-6. 2006..The goals of this phase I study were to determine the maximum tolerated dose (MTD) of IP paclitaxel microspheres and the pharmacology of paclitaxel after IP paclitaxel microsphere administration...